Breaking News Instant updates and real-time market news.

2021-01-15 08:40:51 TKR Timken $85.69 / +1.55 (+1.84%) 08:40 01/15/21 01/15 08:40 01/15/21 08:40	Timken price target raised to $100 from $74 at Jefferies Jefferies analyst Stephen Volkmann raised the firm's price target on Timken to $100 from $74 and keeps a Buy rating on the shares. The December stimulus package, and the increased odds of additional stimulus under Democratic control of Congress, should provide additional tailwinds to growth in industrials, said Volkmann, who raised estimates and prices targets across his machinery coverage.
TKR Timken $85.69 / +1.55 (+1.84%) 01/07/21 Citi Timken price target raised to $95 from $75 at Citi 11/13/20 KeyBanc Timken price target raised to $85 from $68 at KeyBanc 11/02/20 Citi Timken initiated with a Buy at Citi

2021-01-15 08:40:51

TKR

Timken

$85.69 / +1.55 (+1.84%)

08:40

01/15/21

01/15

08:40

01/15/21

08:40

Timken price target raised to $100 from $74 at Jefferies

Jefferies analyst Stephen Volkmann raised the firm's price target on Timken to $100 from $74 and keeps a Buy rating on the shares. The December stimulus package, and the increased odds of additional stimulus under Democratic control of Congress, should provide additional tailwinds to growth in industrials, said Volkmann, who raised estimates and prices targets across his machinery coverage.

TKR Timken

$85.69 / +1.55 (+1.84%)

01/07/21 Citi: Timken price target raised to $95 from $75 at Citi

11/13/20 KeyBanc: Timken price target raised to $85 from $68 at KeyBanc

11/02/20 Citi: Timken initiated with a Buy at Citi

TODAY'S FREE FLY STORIES

Downgrade	Regency Centers downgraded to Hold from Buy at Argus » 07:27 03/04/21 03/04 07:27 03/04/21 07:27 REG Regency Centers $56.67 / +2.525 (+4.66%) Argus analyst Jacob… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options REG Regency Centers $56.67 / +2.525 (+4.66%) 03/02/21 PS Business Parks appoints Dan Chandler as CEO 03/02/21 Regency Centers chief investment officer Mac Chandler to resign 01/27/21 Regency Centers issues TCFD Climate Change Risk Report 01/19/21 Regency Centers sold five shopping centers in Q4 for $77.8M REG Regency Centers $56.67 / +2.525 (+4.66%) 01/25/21 Compass Point Regency Centers upgraded to Buy from Neutral at Compass Point 12/30/20 Truist Regency Centers price target raised to $50 from $45 at Truist 08/19/20 Fly Intel: Top five analyst downgrades 08/19/20 Compass Point Compass Point downgrades Regency Centers on 'tactical valuation call' REG Regency Centers $56.67 / +2.525 (+4.66%) 02/11/21 Regency Centers sees FY21 FFO $2.96-$3.14, consensus $3.31 02/11/21 Regency Centers reports Q4 FFO 76c, consensus 72c 11/05/20 Regency Centers reports Q3 EPS 7c, consensus 21c REG Regency Centers $56.67 / +2.525 (+4.66%) 12/29/20 Early notable gainers among liquid option names on December 29th
Hot Stocks	NewAge enters LOI to acquire Japan-based Aliven for approx. 1M shares » 07:26 03/04/21 03/04 07:26 03/04/21 07:26 NBEV NewAge $2.82 / -0.1 (-3.43%) NewAge announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge announces $58M private placement 12/01/20 NewAge announces $30M debt facility 11/19/20 NewAge appoints Fred Cooper to board of directors 10/15/20 NewAge's DSD Division on track for double-digit organic growth in 2020 NBEV NewAge $2.82 / -0.1 (-3.43%) 07/21/20 Alliance Global Partners New Age Beverages price target raised to $5 from $3.50 at Alliance Global 04/14/20 Alliance Global Partners New Age Beverages at Alliance Global Partners 03/11/20 Compass Point New Age Beverages price target lowered to $4 from $9 at Compass Point NBEV NewAge $2.82 / -0.1 (-3.43%) 02/16/21 NewAge ses Q4 net revenue in $90M range, consensus $79.34M 11/09/20 NewAge reports Q3 EPS (14c), consensus (6c) NBEV NewAge $2.82 / -0.1 (-3.43%) 11/09/20 Fly Intel: Pre-market Movers 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 NewAge - NBEV
Recommendations	Main Street price target raised to $40 from $34 at RBC Capital » 07:25 03/04/21 03/04 07:25 03/04/21 07:25 MAIN Main Street $37.33 / +0.63 (+1.72%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MAIN Main Street $37.33 / +0.63 (+1.72%) 01/20/21 Main Street reports Q4 private loan activity 01/19/21 Capital Southwest supports O2's investment in Flip Electronics 01/07/21 Main Street announces new portfolio investment MAIN Main Street $37.33 / +0.63 (+1.72%) 08/12/20 Truist Main Street price target raised to $33 from $28 at Truist 04/15/20 National Securities Main Street downgraded to Neutral from Buy at National Securities 03/17/20 National Securities Main Street upgraded to Buy from Neutral at National Securities MAIN Main Street $37.33 / +0.63 (+1.72%) 02/25/21 Main Street reports Q4 NII 59c, consensus 51c 11/05/20 Main Street reports Q3 NII 46c, consensus 47c
Recommendations	Exxon Mobil price target raised to $60 from $57 at Morgan Stanley » 07:25 03/04/21 03/04 07:25 03/04/21 07:25 XOM Exxon Mobil $56.52 / +0.45 (+0.80%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil must change direction, not just appoint board candidates, CURE says 03/03/21 Exxon Mobil sees FY21 capital spending $16B-$19B 03/01/21 Michael Angelakis and Jeffrey Ubben join ExxonMobil board 02/24/21 Exxon Mobil to sell U.K. upstream central and northern North Sea assets XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 07:13 Today Truist Exxon Mobil price target raised to $60 from $50 at Truist 06:14 Today Citi Exxon Mobil price target raised to $53 from $44 at Citi 03/02/21 Wells Fargo Exxon Mobil price target raised to $65 from $53 at Wells Fargo 02/26/21 Barclays Exxon Mobil price target raised to $65 from $59 at Barclays XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 02/02/21 Exxon Mobil reports Q4 ex-items EPS 3c, consensus 1c 02/01/21 Notable companies reporting before tomorrow's open 02/01/21 Notable companies reporting before tomorrow's open 12/30/20 Exxon Mobil says Q4 income boosted by up to $600M from gas prices XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/02/21 Exxon CEO says economics, policies creating carbon capture market, Reuters says 03/01/21 Ubben, Angelakis to join board of Exxon Mobil, CNBC reports 02/17/21 Texas prohibits natgas firms from taking fuel out of state, Bloomberg says 02/17/21 Saudis to raise oil output as prices recover, WSJ reports XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/01/21 Fly Intel: Wall Street's top stories for Monday 03/01/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: Pre-market Movers 02/02/21 Fly Intel: Wall Street's top stories for Tuesday XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil call volume above normal and directionally bullish 03/01/21 Unusually active option classes on open March 1st 02/09/21 Unusually active option classes on open February 9th 02/08/21 Exxon Mobil call volume above normal and directionally bullish
Hot Stocks	VBL Therapeutics announces publication of interim analysis of OVAL study » 07:24 03/04/21 03/04 07:24 03/04/21 07:24 VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) VBL Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 03/01/21 VBL Therapeutics announces patient dosing in VB-111 trial 02/22/21 VBL Therapeutics says DSMC recommends continuation of OVAL Phase 3 study 01/27/21 VBL Therapeutics doses first patient in Phase 2 study of VB-201 01/15/21 VBL Therapeutics enters into share purchase agreement with Aspire Capital VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 01/28/21 H.C. Wainwright VBL Therapeutics price target raised to $4 from $3 at H.C. Wainwright VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 11/16/20 VBL Therapeutics reports Q3 EPS (12c), consensus (13c) VBLT VBL Therapeutics $1.83 / -0.12 (-6.15%) 12/30/20 Fly Intel: After-Hours Movers 03/15/21 33rd Annual Roth Virtual Conference 03/16/21 31st Annual Healthcare Virtual Conference

Hot Stocks	Fulcrum Therapeutics CEO Robert Gould to retire, Bryan Stuart to succeed » 07:23 03/04/21 03/04 07:23 03/04/21 07:23 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) Fulcrum Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:16 Today Fulcrum Therapeutics expects cash to fund requirements into 4Q22 07:16 Today Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Recommendations	General Electric price target raised to $17 from $13 at Morgan Stanley » 07:22 03/04/21 03/04 07:22 03/04/21 07:22 GE General Electric $13.45 / +0.48 (+3.70%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GE General Electric $13.45 / +0.48 (+3.70%) 02/24/21 Altair acquires Flow Simulator sofftware from GE Aviation 02/17/21 General Electric focusing on growing through existing business lines, CEO says 02/17/21 General Electric CEO says unlikely to do large M&A deals soon 02/12/21 Trian Fund exits nVent, increases stake in GE GE General Electric $13.45 / +0.48 (+3.70%) 03/02/21 Barclays Danaher started at Overweight at Barclays on GE biopharma business potential 02/22/21 Goldman Sachs General Electric price target raised to $15 at Goldman Sachs after meetings 01/28/21 Barclays General Electric price target raised to $13 from $12 at Barclays 01/27/21 Morgan Stanley General Electric price target raised to $13 from $12 at Morgan Stanley GE General Electric $13.45 / +0.48 (+3.70%) 01/26/21 General Electric sees FY21 adjusted EPS 15c-25c, consensus 38c 01/26/21 General Electric reports Q4 adjusted EPS 8c, consensus 9c 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open GE General Electric $13.45 / +0.48 (+3.70%) 02/16/21 General Electric sees negative cash flow in Q1, Reuters reports 02/11/21 Southwest in talks for at least 300 new 150-seat planes, Air Current says 01/14/21 GE says Siemens stole trade secrets in bid to rig contracts , Reuters reports 01/11/21 GE to pause donations to lawmakers who voted against Biden win, Bloomberg says GE General Electric $13.45 / +0.48 (+3.70%) 01/27/21 Nokia soars but company 'not aware' of apparent reason for trading activity 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Pre-market Movers 11/24/20 Target upgrade, Microsoft initiation among today's top calls on Wall Street 03/10/21 General Electric Co. GE General Electric $13.45 / +0.48 (+3.70%) 02/24/21 General Electric call volume above normal and directionally bullish 01/26/21 Early notable gainers among liquid option names on January 26th 01/06/21 General Electric call volume above normal and directionally bullish 12/23/20 Notable open interest changes for December 23rd
Hot Stocks	DeepGreen Metals enters $2.9B combination agreement with SOAC » 07:22 03/04/21 03/04 07:22 03/04/21 07:22 SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) DeepGreen Metals … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Periodicals Options SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) 02/23/21 DeepGreen Metals in talks to become public through SOAC merger, Bloomberg says SOAC Sustainable Opportunities Acquisition Corp. $10.22 / -0.2 (-1.92%) 03/02/21 Sustainable Opportunities Acquisition Corp (Class A Stock) call volume above normal and directionally bullish
Hot Stocks	Kronos Bio to initiate Phase 3 trial of entospletinib in mid-2021 » 07:21 03/04/21 03/04 07:21 03/04/21 07:21 KRON Kronos Bio $28.75 / -0.66 (-2.24%) Kronos Bio announced,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options KRON Kronos Bio $28.75 / -0.66 (-2.24%) 02/25/21 Kronos Bio announces first patient dosed in Phase 1/2 KB-0742 trial 01/26/21 Kronos Bio appoints Marianne De Backer to board of directors 12/08/20 Kronos Bio appoints Pasit Phiasivongsa as SVP, pharmaceutical development 12/07/20 Kronos Bio announces FDA clearance of IND application for KB-0742 KRON Kronos Bio $28.75 / -0.66 (-2.24%) 11/03/20 Fly Intel: Top five analyst initiations 11/03/20 Jefferies Kronos Bio initiated with a Buy at Jefferies 11/03/20 Piper Sandler Kronos Bio initiated with an Overweight at Piper Sandler 11/03/20 Goldman Sachs Kronos Bio initiated with a Buy at Goldman Sachs KRON Kronos Bio $28.75 / -0.66 (-2.24%) 11/18/20 Kronos Bio reports Q3 EPS ($6.48), consensus ($1.47) 09 Oct KRON Kronos Bio $28.75 / -0.66 (-2.24%) 10/11/20 Opening Day: iHuman makes trading debut amid U.S.-China tensions KRON Kronos Bio $28.75 / -0.66 (-2.24%) 01/28/21 new option listings on January 28th
Hot Stocks	Sol-Gel Technologies expects cash to fund requirements into 3Q22 » 07:20 03/04/21 03/04 07:20 03/04/21 07:20 SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) As of December 31, 2020,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 12/07/20 Sol-Gel Technologies announces FDA acceptance of NDA filing for Twyneo 11/12/20 Sol-Gel Technologies expects cash to fund operations into 3Q21 09/10/20 Sol-Gel Technologies NDA for Epsolay accepted for filing by FDA SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 03/26/20 H.C. Wainwright Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 07:19 Today Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) 11/12/20 Sol-Gel Technologies reports Q3 EPS (37c), consensus (46c) SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 09/11/20 Fly Intel: Pre-market Movers

Hot Stocks	Shift4 Payments announces acquisition of VenueNext, terms undisclosed » 07:19 03/04/21 03/04 07:19 03/04/21 07:19 FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) Shift4 Payments announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 01/07/21 Shift4 Payments, Sightline Payments announce strategic parntership 12/01/20 Shift4 Payments falls -7.8% 11/05/20 Shift4 Payments acquires 3dcart ecommerce platform, terms not disclosed 10/14/20 Shift4 Payments sees Q3 payment volume $7.0B-$7.1B FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 01/06/21 Wolfe Research Shift4 Payments downgraded to Peer Perform from Outperform at Wolfe Research 01/06/21 BofA Shift4 Payments double-downgraded to Underperform from Buy at BofA 12/21/20 Fly Intel: Top five analyst initiations 12/21/20 Piper Sandler Shift4 Payments initiated with an Overweight at Piper Sandler FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 07:09 Today Shift4 Payments sees FY21 revenue $1.1B-$1.2B, consensus $1.08B 07:06 Today Shift4 Payments reports Q4 adjusted EPS (5c), consensus 2c 11/05/20 Shift4 Payments reports Q3 EPS (12c), consensus 5c 11/04/20 Notable companies reporting before tomorrow's open 03 Dec 11 Sep 05 Jun FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 11/30/20 Fly Intel: After-Hours Movers 11/05/20 Fly Intel: Pre-market Movers 08:30 Today Shift4 Payments - FOUR FOUR Shift4 Payments $71.06 / -4.24 (-5.63%) 12/14/20 Largest borrow rate increases among liquid names
Earnings	Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) » 07:19 03/04/21 03/04 07:19 03/04/21 07:19 SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) Reports 2020 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 12/07/20 Sol-Gel Technologies announces FDA acceptance of NDA filing for Twyneo 11/12/20 Sol-Gel Technologies expects cash to fund operations into 3Q21 09/10/20 Sol-Gel Technologies NDA for Epsolay accepted for filing by FDA SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 03/26/20 H.C. Wainwright Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 11/12/20 Sol-Gel Technologies reports Q3 EPS (37c), consensus (46c) SLGL Sol-Gel Technologies $9.58 / -0.05 (-0.52%) 09/11/20 Fly Intel: Pre-market Movers
Downgrade	Retail Properties of America downgraded to Sector Weight at KeyBanc » 07:18 03/04/21 03/04 07:18 03/04/21 07:18 RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 12/08/20 Retail Properties of America raises quarterly dividend to 6c from 5c per share 09/08/20 Retail Properties of America resumes dividend payment and provides update RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 05:20 Today KeyBanc Retail Properties downgraded to Sector Weight from Overweight at KeyBanc 12/15/20 Citi Retail Properties of America price target raised to $9.50 from $7 at Citi 11/10/20 Compass Point Compass Point upgrades four retail REITs to Neutral after Pfizer 'game changer' 11/09/20 Compass Point Retail Properties of America upgraded to Neutral from Sell at Compass Point RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 02/16/21 Retail Properties of America sees FY21 operating FFO 76c-84c 02/16/21 Retail Properties of America reports Q4 operating FFO 20c, consensus 21c 11/02/20 Retail Properties of America reports Q3 operating FFO 21, consensus 20c 05/05/21 Retail Properties of America - RPAI
Hot Stocks	Fulcrum Therapeutics expects cash to fund requirements into 4Q22 » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) The company said,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:16 Today Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Upgrade	Site Centers upgraded to Overweight at KeyBanc » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 SITC Site Centers $12.89 / +0.1 (+0.78%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events SITC Site Centers $12.89 / +0.1 (+0.78%) 01/12/21 Site Centers provides Q4 operational update SITC Site Centers $12.89 / +0.1 (+0.78%) 05:19 Today KeyBanc Site Centers upgraded to Overweight from Sector Weight at KeyBanc 02/23/21 Mizuho Site Centers price target raised to $13 from $10.50 at Mizuho 01/14/21 Piper Sandler Site Centers upgraded to Overweight from Neutral at Piper Sandler 12/15/20 Citi Site Centers price target raised to $11 from $8.50 at Citi SITC Site Centers $12.89 / +0.1 (+0.78%) 02/18/21 Site Centers sees 2021 operating FFO 90c-$1.00, consensus 98c 02/18/21 Site Centers reports Q4 operating FFO 25c, consensus 24c 10/27/20 Site Centers reports Q3 operating FFO 23c, consensus 23c 02 Mar 03/17/21 Site Centers

Hot Stocks	Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) After careful… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program 11/10/20 Fulcrum Therapeutics: Curtis Oltmans to join as general counsel FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 07:15 Today Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Initiation	Wheaton Precious Metals initiated with an Overweight at JPMorgan » 07:16 03/04/21 03/04 07:16 03/04/21 07:16 WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) JPMorgan analyst Tyler… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/10/21 Wheaton Precious Metals sees 2021 production 720K-780K gold eq. oz. 02/01/21 Silver producers up in pre-market on r/wallstreetbets short squeeze speculation 12/11/20 Wheaton Precious Metals to acquire Mexico silver stream from Capstone for $150M 11/09/20 Wheaton Precious Metals raises quarterly dividend 20% to 12c per share WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 03/01/21 Berenberg Wheaton Precious Metals price target raised to 3,700 GBp at Berenberg 02/16/21 Berenberg Wheaton Precious Metals price target lowered to 3,500 GBp from 3,700 GBp at Berenberg 02/08/21 Stifel Wheaton Precious Metals upgraded to Buy from Hold at Stifel 02/02/21 Credit Suisse Wheaton Precious Metals price target lowered to C$62 from C$64 at Credit Suisse WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 11/09/20 Wheaton Precious Metals reports Q3 EPS 33c, consensus 33c WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/01/21 CME raises Silver futures margins by 18% to curb volatility, Bloomberg says WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/01/21 Fly Intel: Wall Street's top stories for Monday 02/01/21 Fly Intel: Wall Street's top stories at midday 03/12/21 Wheaton Precious Metals - WPM WPM Wheaton Precious Metals $35.82 / -1.05 (-2.85%) 02/17/21 Wheaton Precious Metals call volume above normal and directionally bullish 01/28/21 Wheaton Precious Metals call volume above normal and directionally bullish 01/28/21 Largest borrow rate increases among liquid names 12/09/20 Largest borrow rate increases among liquid names
Earnings	Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) » 07:15 03/04/21 03/04 07:15 03/04/21 07:15 FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) Reports Q4 revenue $4.2M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 12/14/20 X4 Pharmaceuticals appoints Diego Cadavid as CMO 12/09/20 Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease 12/06/20 Fulcrum Therapeutics presents updated data on SCD program 11/10/20 Fulcrum Therapeutics: Curtis Oltmans to join as general counsel FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 03/01/21 Stifel Fulcrum Therapeutics initiated with a Buy at Stifel 10/15/20 Piper Sandler Fulcrum Therapeutics initiated with an Overweight at Piper Sandler 08/12/20 Fly Intel: Top five analyst downgrades 08/12/20 BTIG Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG FULC Fulcrum Therapeutics $14.59 / +0.59 (+4.21%) 11/10/20 Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c) 20 Jan 03/16/21 Healthcare Corporate Access Virtual Day 03/16/21 Healthcare Corporate Access Virtual Day 08:00 Today Fulcrum Therapeutics - FULC
Hot Stocks	Gol Linhas reports preliminary February traffic down 50.3% » 07:15 03/04/21 03/04 07:15 03/04/21 07:15 GOL Gol Linhas $7.32 / -0.03 (-0.41%) Reports preliminary… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Options GOL Gol Linhas $7.32 / -0.03 (-0.41%) 02/04/21 Gol Linhas reports preliminary January traffic down 37.2% 01/08/21 Gol Linhas provides December investor update 01/06/21 Gol Linhas announces preliminary traffic figures for December 12/27/20 Fly Intel: Top five weekend stock stories GOL Gol Linhas $7.32 / -0.03 (-0.41%) 01/28/21 Deutsche Bank Gol Linhas downgraded to Hold on slowing recovery at Deutsche Bank 01/28/21 Deutsche Bank Gol Linhas downgraded to Hold from Buy at Deutsche Bank 01/12/21 Deutsche Bank Gol Linhas price target raised to $15 from $10 at Deutsche Bank 12/21/20 Santander Gol Linhas downgraded to Hold from Buy at Santander GOL Gol Linhas $7.32 / -0.03 (-0.41%) 01/08/21 Gol Linhas sees Q4 EPS (65c), consensus (36c) 10/09/20 Gol Linhas sees Q3 EPS ($1.15), consensus (61c) GOL Gol Linhas $7.32 / -0.03 (-0.41%) 12/26/20 Delta, Southwest among airline stocks that could cruise higher, Barron's says 12/09/20 Boeing 737 MAX quietly restarts commercial flights in Brazil, Reuters says 12/02/20 Boeing nearing 737 MAX comeback with potential United delivery, Bloomberg says GOL Gol Linhas $7.32 / -0.03 (-0.41%) 09/29/20 Largest borrow rate increases among liquid names
Earnings	Schrodinger sees FY21 revenue $124M-$142M, consensus $177.25M » 07:15 03/04/21 03/04 07:15 03/04/21 07:15 SDGR Schrodinger $99.03 / -7.82 (-7.32%) Sees FY21 software… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options SDGR Schrodinger $99.03 / -7.82 (-7.32%) 02/25/21 Schrodinger expands collaboration with Google Cloud 02/24/21 Schrodinger holder David Shaw sells 457.7K shares of common stock 01/19/21 David E Shaw reports 17.2% passive stake in Schrodinger 12/07/20 Schrodinger presents data from MALT1 inhibitor program at ASH SDGR Schrodinger $99.03 / -7.82 (-7.32%) 01/25/21 BMO Capital Schrodinger price target raised to $117 from $97 at BMO Capital 11/23/20 BofA BofA upgrades Schrodinger to Buy after 'major' collaboration announcement 11/23/20 BofA Schrodinger upgraded to Buy from Neutral at BofA 10/12/20 Jefferies Schrodinger upgraded to Buy from Hold at Jefferies SDGR Schrodinger $99.03 / -7.82 (-7.32%) 07:12 Today Schrodinger reports Q4 revenue $33M, consensus $37.87M 11/12/20 Schrodinger reports Q3 EPS 5c, consensus (7c) 13 Aug SDGR Schrodinger $99.03 / -7.82 (-7.32%) 10/26/20 Fly Insider: Selecta, Netflix among week's notable insider trades 08:30 Today Schrodinger - SDGR SDGR Schrodinger $99.03 / -7.82 (-7.32%) 10/30/20 Largest borrow rate increases among liquid names

Initiation	Royal Gold initiated with an Overweight at JPMorgan » 07:14 03/04/21 03/04 07:14 03/04/21 07:14 RGLD Royal Gold $103.58 / -2.95 (-2.77%) JPMorgan analyst Tyler… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RGLD Royal Gold $103.58 / -2.95 (-2.77%) 02/03/21 Royal Gold sees Q3 stream segment sales 48K-53K GEOs 01/12/21 Royal Gold provides Q2 update 11/17/20 Royal Gold raises annual dividend to $1.20 from $1.12 per share 10/13/20 Royal Gold subsidiary sold 56,000 gold equivalent ounces in Q1 RGLD Royal Gold $103.58 / -2.95 (-2.77%) 07:12 Today JPMorgan Franco-Nevada initiated with a Neutral at JPMorgan 01/11/21 RBC Capital Royal Gold upgraded to Outperform from Sector Perform at RBC Capital 01/11/21 RBC Capital Royal Gold upgraded to Outperform from Sector Perform at RBC Capital 11/23/20 Canaccord Royal Gold upgraded to Buy from Hold at Canaccord RGLD Royal Gold $103.58 / -2.95 (-2.77%) 02/03/21 Royal Gold reports Q2 adjusted EPS 92c, consensus 87c 11/04/20 Royal Gold reports Q1 EPS $1.63, consensus 86c
Upgrade	Kite Realty Group upgraded to Overweight at KeyBanc » 07:14 03/04/21 03/04 07:14 03/04/21 07:14 KRG Kite Realty Group $19.46 / +0.31 (+1.62%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 02/23/21 Kite Realty Group board authorizes new $150M share buyback 09/14/20 Kite Realty Group collects over 89% of Q3 base rent, recoveries KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 05:20 Today KeyBanc Kite Realty Group upgraded to Overweight from Sector Weight at KeyBanc 12/10/20 Wells Fargo Kite Realty Group upgraded to Overweight at Wells Fargo 12/10/20 Wells Fargo Kite Realty Group upgraded to Overweight from Equal Weight at Wells Fargo 08/19/20 Fly Intel: Top five analyst downgrades KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 02/11/21 Kite Realty Group sees FY21 adjusted FFO $1.24-$1.34, consensus $1.32 02/11/21 Kite Realty Group reports Q4 adjusted FFO 33c, consensus 31c 03/16/21 Kite Realty Group 03/16/21 Kite Realty Group 05/12/21 Kite Realty Group Trust
Hot Stocks	VYNE Therapeutics expects cash to fund requirements through end of 2022 » 07:14 03/04/21 03/04 07:14 03/04/21 07:14 VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) The company said,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 03/01/21 VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3 02/11/21 VYNE Therapeutics approves 1-for-4 reverse stock split 02/01/21 VYNE Therapeutics' Amzeeq label update approved by FDA 01/29/21 VYNE Therapeutics expects cash to fund requirements through end of 2022 VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 10/05/20 H.C. Wainwright VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 07:13 Today VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c) 11/05/20 VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) 08:30 Today VYNE Therapeutics - VYNE VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 02/26/21 Eleven new option listings on February 26th 09/21/20 Seven new option listings and seven option delistings on September 21st 09/08/20 One new option listing and two option delistings on September 8th
Recommendations	Exxon Mobil price target raised to $60 from $50 at Truist » 07:13 03/04/21 03/04 07:13 03/04/21 07:13 XOM Exxon Mobil $56.52 / +0.45 (+0.80%) Truist analyst Welles… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil must change direction, not just appoint board candidates, CURE says 03/03/21 Exxon Mobil sees FY21 capital spending $16B-$19B 03/01/21 Michael Angelakis and Jeffrey Ubben join ExxonMobil board 02/24/21 Exxon Mobil to sell U.K. upstream central and northern North Sea assets XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 06:14 Today Citi Exxon Mobil price target raised to $53 from $44 at Citi 03/02/21 Wells Fargo Exxon Mobil price target raised to $65 from $53 at Wells Fargo 02/26/21 Barclays Exxon Mobil price target raised to $65 from $59 at Barclays 02/16/21 Credit Suisse Exxon Mobil price target raised to $62 from $52 at Credit Suisse XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 02/02/21 Exxon Mobil reports Q4 ex-items EPS 3c, consensus 1c 02/01/21 Notable companies reporting before tomorrow's open 02/01/21 Notable companies reporting before tomorrow's open 12/30/20 Exxon Mobil says Q4 income boosted by up to $600M from gas prices XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/02/21 Exxon CEO says economics, policies creating carbon capture market, Reuters says 03/01/21 Ubben, Angelakis to join board of Exxon Mobil, CNBC reports 02/17/21 Texas prohibits natgas firms from taking fuel out of state, Bloomberg says 02/17/21 Saudis to raise oil output as prices recover, WSJ reports XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/01/21 Fly Intel: Wall Street's top stories for Monday 03/01/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: Pre-market Movers 02/02/21 Fly Intel: Wall Street's top stories for Tuesday XOM Exxon Mobil $56.52 / +0.45 (+0.80%) 03/03/21 Exxon Mobil call volume above normal and directionally bullish 03/01/21 Unusually active option classes on open March 1st 02/09/21 Unusually active option classes on open February 9th 02/08/21 Exxon Mobil call volume above normal and directionally bullish
Earnings	VYNE Therapeutics reports Q4 adjusted EPS (43c) , consensus (53c) » 07:13 03/04/21 03/04 07:13 03/04/21 07:13 VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 03/01/21 VYNE Therapeutics to begin Phase 2a study of FMX114 in Q3 02/11/21 VYNE Therapeutics approves 1-for-4 reverse stock split 02/01/21 VYNE Therapeutics' Amzeeq label update approved by FDA 01/29/21 VYNE Therapeutics expects cash to fund requirements through end of 2022 VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 10/05/20 H.C. Wainwright VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 11/05/20 VYNE Therapeutics reports Q3 adj. EPS (13c), consensus (17c) 08:30 Today VYNE Therapeutics - VYNE VYNE VYNE Therapeutics $7.38 / +0.1 (+1.37%) 02/26/21 Eleven new option listings on February 26th 09/21/20 Seven new option listings and seven option delistings on September 21st 09/08/20 One new option listing and two option delistings on September 8th

Events

Earnings calls, analyst events, roadshows and more

Today at 07:30

Challenger Job-Cut Report Level: February 2021 Government Event
HCM
Today at 08:00

Hutchison China MediTech - HCM Conference Calls
BALY
Today at 08:00

Bally's - BALY Conference Calls
ATC
Today at 08:00

Atotech - ATC Conference Calls
WVE
Today at 08:00

Wave Life Sciences - WVE Conference Calls
FULC
Today at 08:00

Fulcrum Therapeutics - FULC Conference Calls
Today at 08:00

Consumer Data Analytics Industry Meetings
Today at 08:30

Initial Jobless Claims Change: Week 2/27/2021 Government Event
Today at 08:30

Jobless Claims: 4-Week Moving Average: Week 2/27/2021 Government Event
Today at 08:30

Productivity & Costs: Non-farm Poductivity Annual Rate: Q4(r):2020 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson Priced at: $41.00 4.95M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DGII X DGII Digi International Secondary Managers: Piper Sandler Priced at: $19.50 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities Priced at: $18.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	EYE X EYE National Vision Block Trade Managers: JPMorgan $46.50-47.00 3.9M Shares AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LASR X LASR nLight Spot Secondary Managers: Stifel & Raymond James $34.00-35.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR $11.50-11.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial STX X STX Seagate Spot Secondary Managers: JPMorgan $75.94 4.65M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Timken price target raised to $100 from $74 at Jefferies

TODAY'S FREE FLY STORIES

Get Full Fly Access